Meeting News Coverage

Early CNV detection with home monitoring yields better visual acuity outcomes

NEW ORLEANS — Patients at high risk for progression of age-related macular degeneration would benefit from using a home monitoring device strategy to detect early development of choroidal neovascularization, according to a presenter here.

Earlier detection would increase the likelihood of maximizing visual acuity after later intravitreal anti-VEGF therapy, Susan B. Bressler, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Citing results of the HOME study published this month in Ophthalmology, Bressler said, “Our objective was to perform a randomized trial to determine if home monitoring using the comprehensive visual field and telemonitoring solution based on the ForeseeHome device (Notal Vision) plus standard of care would improve the detection of progression to CNV when compared with standard care monitoring methods.”

Of 1,520 participants in the HOME study, some culled from the AREDS2 patient pool, 757 received standard care and 763 were randomized to the ForeseeHome device monitoring arm. Primary outcome was change in visual acuity from baseline at CNV detection.

In the device arm, 51 CNV events were detected; in the standard care arm, 31 CNV events were detected. The proportion of eyes maintaining visual acuity of 20/40 or better increased 43% to 51% in the device arm, Bressler said.

Reference:
The AREDS2-HOME Study Research Group. Ophthalmology. 2013;doi:10.1016/j.ophtha.2013.10.027.

Disclosure: Bressler is a consultant for Glaxo and receives grant support from Allergan, Bausch + Lomb, Genentech, Lumenis, Notal Vision, Novartis, Regeneron, Research to Prevent Blindness and EMMES.

NEW ORLEANS — Patients at high risk for progression of age-related macular degeneration would benefit from using a home monitoring device strategy to detect early development of choroidal neovascularization, according to a presenter here.

Earlier detection would increase the likelihood of maximizing visual acuity after later intravitreal anti-VEGF therapy, Susan B. Bressler, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Citing results of the HOME study published this month in Ophthalmology, Bressler said, “Our objective was to perform a randomized trial to determine if home monitoring using the comprehensive visual field and telemonitoring solution based on the ForeseeHome device (Notal Vision) plus standard of care would improve the detection of progression to CNV when compared with standard care monitoring methods.”

Of 1,520 participants in the HOME study, some culled from the AREDS2 patient pool, 757 received standard care and 763 were randomized to the ForeseeHome device monitoring arm. Primary outcome was change in visual acuity from baseline at CNV detection.

In the device arm, 51 CNV events were detected; in the standard care arm, 31 CNV events were detected. The proportion of eyes maintaining visual acuity of 20/40 or better increased 43% to 51% in the device arm, Bressler said.

Reference:
The AREDS2-HOME Study Research Group. Ophthalmology. 2013;doi:10.1016/j.ophtha.2013.10.027.

Disclosure: Bressler is a consultant for Glaxo and receives grant support from Allergan, Bausch + Lomb, Genentech, Lumenis, Notal Vision, Novartis, Regeneron, Research to Prevent Blindness and EMMES.